HBM 1027
Alternative Names: HBM1027; R-1027Latest Information Update: 28 Oct 2023
At a glance
- Originator Harbour BioMed
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for research development in Autoimmune-disorders in China (Parenteral)
- 12 Sep 2019 Early research in Autoimmune disorders in China (Parenteral) (Harbour BioMed pipeline, September 2019)